Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dharminder Chauhan, Ph.D., J.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA207237 (ANDERSON, KENNETH C.) Jul 15, 2016 - Jun 30, 2021
    NIH/NCI
    Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Du T, Song Y, Ray A, Chauhan D, Anderson KC. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13. Leukemia. 2020 May 18. PMID: 32424294.
    Citations:    
  2. Schauer NJ, Liu X, Magin RS, Doherty LM, Chan WC, Ficarro SB, Hu W, Roberts RM, Iacob RE, Stolte B, Giacomelli AO, Perera S, McKay K, Boswell SA, Weisberg EL, Ray A, Chauhan D, Dhe-Paganon S, Anderson KC, Griffin JD, Li J, Hahn WC, Sorger PK, Engen JR, Stegmaier K, Marto JA, Buhrlage SJ. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020 Mar 24; 10(1):5324. PMID: 32210275.
    Citations:    
  3. Richardson PG, Bringhen S, Voorhees P, Plesner T, Mellqvist UH, Reeves B, Paba-Prada C, Zubair H, Byrne C, Chauhan D, Anderson K, Nordström E, Harmenberg J, Palumbo A, Sonneveld P. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020 May; 7(5):e395-e407. PMID: 32213344.
    Citations:    
  4. Ray A, Song Y, Du T, Chauhan D, Anderson KC. Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma. Oncogene. 2020 Mar; 39(13):2786-2796. PMID: 32024967.
    Citations:    
  5. Ray A, Song Y, Du T, Tai YT, Chauhan D, Anderson KC. Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma. Leukemia. 2020 Feb; 34(2):567-577. PMID: 31462737.
    Citations:    
  6. Ray A, Song Y, Chauhan D, Anderson KC. Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity. Blood Cancer J. 2019 08 12; 9(8):64. PMID: 31406111.
    Citations:    
  7. Song Y, Park PMC, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC, Qi J, Chauhan D. Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia. 2019 11; 33(11):2685-2694. PMID: 30962579.
    Citations:    
  8. Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG. The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018 12; 15(12):1033-1052. PMID: 30427223.
    Citations:    Fields:    
  9. Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017 12; 36(4):561-584. PMID: 29196868.
    Citations: 5     Fields:    Translation:Humans
  10. Spencer A, Harrison S, Zonder J, Badros A, Laubach J, Bergin K, Khot A, Zimmerman T, Chauhan D, Levin N, MacLaren A, Reich SD, Trikha M, Richardson P. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. Br J Haematol. 2018 01; 180(1):41-51. PMID: 29076150.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  11. Lamberto I, Liu X, Seo HS, Schauer NJ, Iacob RE, Hu W, Das D, Mikhailova T, Weisberg EL, Engen JR, Anderson KC, Chauhan D, Dhe-Paganon S, Buhrlage SJ. Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. Cell Chem Biol. 2017 12 21; 24(12):1490-1500.e11. PMID: 29056421.
    Citations: 6     Fields:    Translation:HumansCells
  12. Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215. PMID: 28967922.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  13. Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J. Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Sep 12; 8(39):66641-66655. PMID: 29029544.
    Citations:    Fields:    
  14. Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J. Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Jun 08. PMID: 28621266.
    Citations:    
  15. Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC. Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2017 Aug 01; 23(15):4280-4289. PMID: 28270494.
    Citations: 3     Fields:    Translation:HumansCells
  16. Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319. PMID: 28082445.
    Citations: 1     Fields:    Translation:HumansCells
  17. Cea M, Cagnetta A, Acharya C, Acharya P, Tai YT, Yang C, Lovera D, Soncini D, Miglino M, Fraternali-Orcioni G, Mastracci L, Nencioni A, Montecucco F, Monacelli F, Ballestrero A, Hideshima T, Chauhan D, Gobbi M, Lemoli RM, Munshi N, Treon SP, Anderson KC. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109. PMID: 27287071.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  18. Levin N, Spencer A, Harrison SJ, Chauhan D, Burrows FJ, Anderson KC, Reich SD, Richardson PG, Trikha M. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol. 2016 Sep; 174(5):711-20. PMID: 27161872.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  19. Ray A, Ravillah D, Das DS, Song Y, Nordström E, Gullbo J, Richardson PG, Chauhan D, Anderson KC. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016 08; 174(3):397-409. PMID: 27098276.
    Citations: 2     Fields:    Translation:HumansCells
  20. Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, Laubach JP, Chauhan D, Jakubowiak AJ, Reich S, Trikha M, Anderson KC. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 06 02; 127(22):2693-700. PMID: 27009059.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  21. Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50. PMID: 26675349.
    Citations: 13     Fields:    Translation:HumansCells
  22. Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H, Yoshida Y, Sagawa M, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi N, Ando K, Utsugi T, Hideshima T, Anderson KC. Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015; 10(12):e0143847. PMID: 26630652.
    Citations: 4     Fields:    Translation:HumansCells
  23. Das DS, Ray A, Song Y, Richardson P, Trikha M, Chauhan D, Anderson KC. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. Br J Haematol. 2015 Dec; 171(5):798-812. PMID: 26456076.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  24. Varga C, Laubach J, Hideshima T, Chauhan D, Anderson KC, Richardson PG. Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):903-25. PMID: 25212889.
    Citations: 2     Fields:    Translation:Humans
  25. Jones DR, Wu Z, Chauhan D, Anderson KC, Peng J. A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma. Anal Chem. 2014 Apr 01; 86(7):3667-75. PMID: 24611431.
    Citations: 4     Fields:    Translation:Humans
  26. Garcia-Gomez A, Quwaider D, Canavese M, Ocio EM, Tian Z, Blanco JF, Berger AJ, Ortiz-de-Solorzano C, Hernández-Iglesias T, Martens AC, Groen RW, Mateo-Urdiales J, Fraile S, Galarraga M, Chauhan D, San Miguel JF, Raje N, Garayoa M. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin Cancer Res. 2014 Mar 15; 20(6):1542-54. PMID: 24486586.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  27. Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014 Jan 30; 123(5):706-16. PMID: 24319254.
    Citations: 73     Fields:    Translation:HumansAnimalsCells
  28. Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013 Aug 15; 122(7):1243-55. PMID: 23823317.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  29. Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N, Richardson P, Lewensohn R, Anderson KC. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun 01; 19(11):3019-31. PMID: 23584492.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  30. Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC, Richardson PG. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012 Dec; 7(4):258-66. PMID: 23065395.
    Citations: 23     Fields:    Translation:Humans
  31. Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chauhan D, Anderson KC. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 08; 120(19):3958-67. PMID: 22983447.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
  32. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, Anderson KC. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58. PMID: 22975377.
    Citations: 114     Fields:    Translation:HumansAnimalsCells
  33. Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29. PMID: 22955917.
    Citations: 38     Fields:    Translation:HumansAnimalsCells
  34. Chauhan D, Anderson KC. Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas. BMC Biol. 2011 Oct 28; 9:72. PMID: 22034840.
    Citations: 1     Fields:    Translation:AnimalsCells
  35. Chauhan D, Bandi M, Singh AV, Ray A, Raje N, Richardson P, Anderson KC. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br J Haematol. 2011 Dec; 155(5):588-98. PMID: 21950728.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  36. Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jäger D, Olson DL, Sattler M, Chauhan D, Anderson KC. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol. 2011 Nov; 155(4):438-48. PMID: 21923653.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  37. Richardson PG, Laubach J, Mitsiades CS, Schlossman R, Hideshima T, Redman K, Chauhan D, Ghobrial IM, Munshi N, Anderson KC. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62. PMID: 21732930.
    Citations: 5     Fields:    Translation:Humans
  38. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15; 17(16):5311-21. PMID: 21724551.
    Citations: 82     Fields:    Translation:HumansAnimalsCells
  39. Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood. 2011 May 26; 117(21):5692-700. PMID: 21454451.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  40. Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15; 17(10):3259-71. PMID: 21430070.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  41. Singh AV, Bandi M, Aujay MA, Kirk CJ, Hark DE, Raje N, Chauhan D, Anderson KC. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol. 2011 Jan; 152(2):155-63. PMID: 21114484.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  42. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 02; 116(23):4906-15. PMID: 20805366.
    Citations: 48     Fields:    Translation:HumansAnimalsCells
  43. Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol. 2010 May; 149(4):550-9. PMID: 20331453.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  44. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May; 149(4):537-49. PMID: 20331454.
    Citations: 42     Fields:    Translation:HumansAnimalsCells
  45. Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, Hideshima H, Munshi NC, Richardson PG, Carrasco DR, Anderson KC. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5. PMID: 20228272.
    Citations: 18     Fields:    Translation:HumansCells
  46. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5124-9. PMID: 20194748.
    Citations: 68     Fields:    Translation:HumansAnimalsCells
  47. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60. PMID: 19934289.
    Citations: 25     Fields:    Translation:HumansCells
  48. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2010 Jan 28; 115(4):834-45. PMID: 19965674.
    Citations: 37     Fields:    Translation:HumansAnimalsCells
  49. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23. PMID: 19800576.
    Citations: 68     Fields:    Translation:HumansAnimalsCells
  50. Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60. PMID: 19878638.
    Citations: 8     Fields:    Translation:Humans
  51. Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS. In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6. PMID: 19751238.
    Citations: 12     Fields:    Translation:HumansCells
  52. Laubach JP, Mitsiades CS, Hideshima T, Schlossman R, Chauhan D, Munshi N, Ghobrial I, Carreau N, Anderson KC, Richardson PG. Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17. PMID: 21188129.
    Citations: 1     
  53. Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, Raab MS, Vallet S, Zhou Y, Cartron MA, Hideshima T, Tai YT, Chauhan D, Anderson KC, Podar K. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009 Jun 15; 69(12):5082-90. PMID: 19509231.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  54. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009 Jul 30; 114(5):1046-52. PMID: 19436050.
    Citations: 115     Fields:    Translation:HumansAnimalsCells
  55. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 09; 114(2):371-9. PMID: 19417213.
    Citations: 137     Fields:    Translation:HumansAnimalsCells
  56. Mitsiades CS, Hideshima T, Chauhan D, McMillin DW, Klippel S, Laubach JP, Munshi NC, Anderson KC, Richardson PG. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75. PMID: 19389500.
    Citations: 17     Fields:    Translation:HumansAnimals
  57. Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K, Raje N, Protopopov A, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood. 2009 May 21; 113(21):5228-36. PMID: 19270264.
    Citations: 39     Fields:    Translation:HumansCells
  58. Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, Podar K, Catley L, Hideshima T, Chauhan D, Caulder E, Neilan CL, Vaddi K, Li J, Gramatzki M, Fridman JS, Anderson KC. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther. 2009 Jan; 8(1):26-35. PMID: 19139110.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  59. Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T, Fruehauf JH, Lin BK, Chauhan D, Hideshima T, Munshi NC, Anderson KC, Podar K. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009 Feb 12; 113(7):1513-21. PMID: 19018094.
    Citations: 19     Fields:    Translation:HumansCells
  60. Chauhan D, Bianchi G, Anderson KC. Targeting the UPS as therapy in multiple myeloma. BMC Biochem. 2008 Oct 21; 9 Suppl 1:S1. PMID: 19007431.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  61. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC, Frank DA. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15; 112(13):5095-102. PMID: 18824601.
    Citations: 50     Fields:    Translation:HumansCells
  62. Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25. PMID: 18593922.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  63. Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008 May; 141(5):598-606. PMID: 18397345.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  64. Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 01; 111(9):4752-63. PMID: 18316628.
    Citations: 22     Fields:    Translation:HumansCells
  65. Chauhan D, Hideshima T, Anderson KC. Targeting proteasomes as therapy in multiple myeloma. Adv Exp Med Biol. 2008; 615:251-60. PMID: 18437898.
    Citations: 15     Fields:    Translation:HumansAnimals
  66. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1007-34, vii-viii. PMID: 17996586.
    Citations: 42     Fields:    Translation:HumansCells
  67. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 2007 Dec; 20(4):597-612. PMID: 18070708.
    Citations: 27     Fields:    Translation:HumansCells
  68. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008 Feb 01; 111(3):1654-64. PMID: 18006697.
    Citations: 68     Fields:    Translation:HumansAnimalsCells
  69. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D, Munshi NC, Richardson PG, Anderson KC. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol. 2007 Oct; 139(1):55-63. PMID: 17854307.
    Citations: 14     Fields:    Translation:HumansCells
  70. Podar K, Raab MS, Chauhan D, Anderson KC. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs. 2007 Oct; 16(10):1693-707. PMID: 17922632.
    Citations: 21     Fields:    Translation:HumansAnimals
  71. Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, Tassone P, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007 Oct 01; 13(19):5903-9. PMID: 17908986.
    Citations: 42     Fields:    Translation:HumansAnimalsCells
  72. Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007 Sep; 138(6):783-91. PMID: 17760810.
    Citations: 40     Fields:    Translation:HumansAnimalsCells
  73. Catley L, Hideshima T, Chauhan D, Neri P, Tassone P, Bronson R, Song W, Tai YT, Munshi NC, Anderson KC. Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol. 2007 Jul; 35(7):1038-46. PMID: 17588472.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  74. Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007 Jun; 6(6):1718-27. PMID: 17575103.
    Citations: 43     Fields:    Translation:HumansCells
  75. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63. PMID: 17510321.
    Citations: 46     Fields:    Translation:AnimalsCellsCTClinical Trials
  76. Podar K, Richardson PG, Chauhan D, Anderson KC. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2007 Apr; 7(4):551-66. PMID: 17428175.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  77. Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood. 2007 Jul 15; 110(2):709-18. PMID: 17384201.
    Citations: 53     Fields:    Translation:HumansCells
  78. Podar K, Raab MS, Tonon G, Sattler M, Barilà D, Zhang J, Tai YT, Yasui H, Raje N, DePinho RA, Hideshima T, Chauhan D, Anderson KC. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res. 2007 Feb 15; 67(4):1680-8. PMID: 17308109.
    Citations: 32     Fields:    Translation:HumansCells
  79. Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munshi N, Anderson K. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23. PMID: 18024646.
    Citations: 16     Fields:    Translation:Humans
  80. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19478-83. PMID: 17164332.
    Citations: 58     Fields:    Translation:HumansAnimalsCells
  81. Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, Tassone P, Raje N, Mitsiades C, Mitsiades N, Richardson P, Zawel L, Tran M, Munshi N, Anderson KC. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 01; 109(3):1220-7. PMID: 17032924.
    Citations: 44     Fields:    Translation:HumansAnimalsCells
  82. Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT, Lin BK, Munshi N, Hideshima T, Chauhan D, Anderson KC. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007 Feb 15; 109(4):1669-77. PMID: 17023575.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  83. Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94. PMID: 17020997.
    Citations: 53     Fields:    Translation:HumansAnimalsCells
  84. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul; 134(2):145-56. PMID: 16846475.
    Citations: 41     Fields:    Translation:HumansCells
  85. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82. PMID: 16818641.
    Citations: 61     Fields:    Translation:HumansCells
  86. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, Irvine AE. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res. 2006 Jun 15; 66(12):6379-86. PMID: 16778216.
    Citations: 38     Fields:    Translation:HumansCells
  87. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006 Nov 15; 108(10):3441-9. PMID: 16728695.
    Citations: 99     Fields:    Translation:HumansCells
  88. Kumar S, Raje N, Hideshima T, Ishitsuka K, Podar K, Le Gouille S, Chauhan D, Richardson P, Munshi NC, Anderson K. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704. PMID: 16487170.
    Citations:    Fields:    Translation:HumansCells
  89. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006 May 15; 107(10):4053-62. PMID: 16418332.
    Citations: 142     Fields:    Translation:HumansCells
  90. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20. PMID: 16357183.
    Citations: 58     Fields:    Translation:HumansCells
  91. Hideshima T, Bradner JE, Chauhan D, Anderson KC. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8530-3. PMID: 16361533.
    Citations: 8     Fields:    Translation:HumansCells
  92. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005 Nov; 8(5):407-19. PMID: 16286248.
    Citations: 168     Fields:    Translation:HumansAnimalsCells
  93. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100. PMID: 16234364.
    Citations: 86     Fields:    Translation:HumansCells
  94. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005 Sep 15; 65(18):8350-8. PMID: 16166312.
    Citations: 29     Fields:    Translation:HumansCells
  95. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol. 2005 Sep 10; 23(26):6345-50. PMID: 16155018.
    Citations: 19     Fields:    Translation:HumansAnimals
  96. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006 Jan 01; 107(1):301-4. PMID: 16150935.
    Citations: 64     Fields:    Translation:HumansCells
  97. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, Le Gouill S, Shiraishi N, Yasui H, Roccaro AM, Tai YZ, Chauhan D, Fram R, Tamura K, Jain J, Anderson KC. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 01; 24(38):5888-96. PMID: 15940263.
    Citations: 16     Fields:    Translation:HumansCells
  98. Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005 Aug 15; 65(16):7478-84. PMID: 16103102.
    Citations: 36     Fields:    Translation:Cells
  99. Catley L, Tai YT, Chauhan D, Anderson KC. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat. 2005 Aug; 8(4):205-18. PMID: 16019253.
    Citations: 10     Fields:    Translation:Humans
  100. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005 Jun 14; 102(24):8567-72. PMID: 15937109.
    Citations: 181     Fields:    Translation:HumansCells
  101. Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005 Jun 01; 11(11):4251-8. PMID: 15930364.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  102. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood. 2005 Sep 01; 106(5):1794-800. PMID: 15870175.
    Citations: 43     Fields:    Translation:HumansCells
  103. Hideshima T, Chauhan D, Ishitsuka K, Yasui H, Raje N, Kumar S, Podar K, Mitsiades C, Hideshima H, Bonham L, Munshi NC, Richardson PG, Singer JW, Anderson KC. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene. 2005 Apr 28; 24(19):3121-9. PMID: 15735676.
    Citations: 10     Fields:    Translation:HumansCells
  104. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005 Aug 01; 106(3):1042-7. PMID: 15827128.
    Citations: 50     Fields:    Translation:HumansCells
  105. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther. 2005 Apr; 4(4):686-92. PMID: 15827343.
    Citations: 45     Fields:    Translation:HumansAnimals
  106. Podar K, Hideshima T, Chauhan D, Anderson KC. Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin Ther Targets. 2005 Apr; 9(2):359-81. PMID: 15934921.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  107. Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S, Tassone P, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal S, Elliott G, Munshi NC, Anderson KC. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005 Jul 15; 106(2):706-12. PMID: 15802527.
    Citations: 15     Fields:    Translation:HumansCells
  108. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol. 2005; 18(4):509-24. PMID: 16026734.
    Citations: 26     Fields:    Translation:HumansCells
  109. Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol. 2005; 45:465-76. PMID: 15822185.
    Citations: 37     Fields:    Translation:HumansAnimals
  110. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203. PMID: 15638853.
    Citations: 82     Fields:    Translation:HumansCells
  111. Catley L, Tai YT, Shringarpure R, Burger R, Son MT, Podar K, Tassone P, Chauhan D, Hideshima T, Denis L, Richardson P, Munshi NC, Anderson KC. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004 Dec 01; 64(23):8746-53. PMID: 15574786.
    Citations: 9     Fields:    Translation:HumansCells
  112. Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76. PMID: 15480425.
    Citations: 33     Fields:    Translation:HumansCells
  113. Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M, Ishitsuka K, Yasui H, Richardson P, Chakravarty S, Murphy A, Chauhan D, Higgins LS, Anderson KC. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004 Nov 15; 10(22):7540-6. PMID: 15569984.
    Citations: 26     Fields:    Translation:HumansCells
  114. Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004 Oct 15; 64(20):7500-6. PMID: 15492276.
    Citations: 20     Fields:    Translation:HumansCells
  115. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005 Feb 15; 105(4):1717-23. PMID: 15486067.
    Citations: 69     Fields:    Translation:HumansCells
  116. Lin B, Catley L, LeBlanc R, Mitsiades C, Burger R, Tai YT, Podar K, Wartmann M, Chauhan D, Griffin JD, Anderson KC. Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood. 2005 Jan 01; 105(1):350-7. PMID: 15367426.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  117. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi NC, Stirling DI, Antin JH, Anderson KC. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93. PMID: 15319277.
    Citations: 54     Fields:    Translation:HumansCells
  118. Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, Munshi N, Richardson P, Cotter FE, Anderson KC. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004 Oct 15; 104(8):2458-66. PMID: 15217830.
    Citations: 19     Fields:    Translation:HumansCells
  119. Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004 Nov 01; 104(9):2886-92. PMID: 15217829.
    Citations: 33     Fields:    Translation:HumansAnimalsCells
  120. Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52. PMID: 15086415.
    Citations: 15     Fields:    Translation:HumansCells
  121. Chauhan D, Li G, Hideshima T, Podar K, Shringarpure R, Mitsiades C, Munshi N, Yew PR, Anderson KC. Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene. 2004 Apr 29; 23(20):3597-602. PMID: 15094775.
    Citations: 14     Fields:    Translation:Humans
  122. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52. PMID: 15087402.
    Citations: 36     Fields:    Translation:HumansCells
  123. Podar K, Mostoslavsky G, Sattler M, Tai YT, Hayashi T, Catley LP, Hideshima T, Mulligan RC, Chauhan D, Anderson KC. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J Biol Chem. 2004 May 14; 279(20):21658-65. PMID: 15010462.
    Citations: 18     Fields:    Translation:HumansCells
  124. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004 Mar; 5(3):221-30. PMID: 15050914.
    Citations: 143     Fields:    Translation:Humans
  125. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):540-5. PMID: 14695887.
    Citations: 158     Fields:    Translation:HumansCells
  126. Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15; 103(8):3158-66. PMID: 15070698.
    Citations: 25     Fields:    Translation:HumansCells
  127. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C, MItsiades N, Gong B, Bonham L, de Vries P, Munshi N, Richardson PG, Singer JW, Anderson KC. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36. PMID: 14679006.
    Citations: 19     Fields:    Translation:HumansCells
  128. Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, Anderson K. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene. 2003 Nov 27; 22(54):8797-801. PMID: 14647474.
    Citations: 18     Fields:    Translation:HumansCells
  129. Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, Burger R, Schlossman RL, Richardson PG, Pandite LN, Kumar R, Hideshima T, Chauhan D, Anderson KC. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. 2004 May 01; 103(9):3474-9. PMID: 14644994.
    Citations: 11     Fields:    Translation:HumansCells
  130. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003 Nov 20; 22(52):8386-93. PMID: 14627979.
    Citations: 40     Fields:    Translation:HumansCells
  131. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96. PMID: 14583463.
    Citations: 34     Fields:    Translation:HumansAnimals
  132. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003 Oct 01; 63(19):6174-7. PMID: 14559800.
    Citations: 49     Fields:    Translation:HumansCells
  133. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 01; 103(5):1787-90. PMID: 14512311.
    Citations: 69     Fields:    Translation:HumansCells
  134. Chauhan D, Li G, Sattler M, Podar K, Mitsiades C, Mitsiades N, Munshi N, Hideshima T, Anderson KC. Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene. 2003 Sep 18; 22(40):6296-300. PMID: 13679868.
    Citations: 14     Fields:    Translation:HumansCells
  135. Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 Sep 15; 63(18):5850-8. PMID: 14522909.
    Citations: 49     Fields:    Translation:HumansCells
  136. Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, Bergsagel L, Chauhan D, Anderson KC. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 01; 103(5):1799-806. PMID: 12969976.
    Citations: 49     Fields:    Translation:HumansCells
  137. Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther. 2003 Sep; 2(9):825-33. PMID: 14555701.
    Citations: 23     Fields:    Translation:HumansCells
  138. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003 Dec 15; 102(13):4504-11. PMID: 12947006.
    Citations: 70     Fields:    Translation:Humans
  139. Chauhan D, Hideshima T, Anderson KC. Apoptotic signaling in multiple myeloma: therapeutic implications. Int J Hematol. 2003 Aug; 78(2):114-20. PMID: 12953804.
    Citations: 5     Fields:    Translation:Humans
  140. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, Burger R, Munshi N, Ohtake Y, Saxena S, Anderson KC. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003 Nov 01; 102(9):3379-86. PMID: 12855565.
    Citations: 32     Fields:    Translation:HumansCells
  141. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22. PMID: 12816865.
    Citations: 52     Fields:    Translation:HumansAnimalsCells
  142. Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May; 121(4):592-6. PMID: 12752100.
    Citations: 8     Fields:    Translation:Humans
  143. Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, Anderson KC. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003 Aug 15; 102(4):1435-42. PMID: 12714512.
    Citations: 21     Fields:    Translation:HumansCells
  144. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003 Apr; 31(4):271-82. PMID: 12691914.
    Citations: 56     Fields:    Translation:HumansCells
  145. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Munshi N, Kharbanda S, Anderson KC. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003 May 16; 278(20):17593-6. PMID: 12665525.
    Citations: 37     Fields:    Translation:HumansCells
  146. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62. PMID: 12531799.
    Citations: 76     Fields:    Translation:HumansCells
  147. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21. PMID: 12517770.
    Citations: 46     Fields:    Translation:HumansCells
  148. Yamaguchi T, Yamauchi M, Sugimoto T, Chauhan D, Anderson KC, Brown EM, Chihara K. The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation. Biochem Biophys Res Commun. 2002 Dec 13; 299(4):532-8. PMID: 12459170.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  149. Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KC. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801. PMID: 12482878.
    Citations: 27     Fields:    Translation:HumansCells
  150. Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W, Anderson KC. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003 May 01; 101(9):3606-14. PMID: 12480690.
    Citations: 17     Fields:    Translation:Cells
  151. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80. PMID: 12424198.
    Citations: 157     Fields:    Translation:HumansCells
  152. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 Nov 01; 100(9):3063-7. PMID: 12384400.
    Citations: 146     Fields:    Translation:HumansCTClinical Trials
  153. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9. PMID: 12391322.
    Citations: 175     Fields:    Translation:HumansCells
  154. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003 Feb 15; 101(4):1530-4. PMID: 12393500.
    Citations: 138     Fields:    Translation:HumansCells
  155. Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002 Sep 15; 100(6):2187-94. PMID: 12200384.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  156. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, Anderson KC. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003 Jan 15; 101(2):703-5. PMID: 12393542.
    Citations: 31     Fields:    Translation:HumansCells
  157. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83. PMID: 12173037.
    Citations: 123     Fields:    Translation:HumansCells
  158. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002 Aug; 1(10):851-60. PMID: 12492118.
    Citations: 31     Fields:    Translation:HumansCells
  159. Munshi NC, Hideshima T, Chauhan D, Richardson P, Anderson KC. Novel biologically based therapies for multiple myeloma. Int J Hematol. 2002 Aug; 76 Suppl 1:340-1. PMID: 12430878.
    Citations: 2     Fields:    Translation:HumansAnimals
  160. Gupta D, Podar K, Tai YT, Lin B, Hideshima T, Akiyama M, LeBlanc R, Catley L, Mitsiades N, Mitsiades C, Chauhan D, Munshi NC, Anderson KC. beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol. 2002 Jul; 30(7):711-20. PMID: 12135668.
    Citations: 2     Fields:    Translation:HumansCells
  161. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82. PMID: 12097303.
    Citations: 43     Fields:    Translation:HumansCells
  162. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30. PMID: 12036884.
    Citations: 130     Fields:    Translation:HumansCells
  163. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86. PMID: 12010810.
    Citations: 72     Fields:    Translation:HumansCells
  164. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002 May; 1(7):539-44. PMID: 12479272.
    Citations: 33     Fields:    Translation:HumansCells
  165. Semenov I, Akyuz C, Roginskaya V, Chauhan D, Corey SJ. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk Res. 2002 Mar; 26(3):271-80. PMID: 11792416.
    Citations: 12     Fields:    Translation:HumansCells
  166. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47. PMID: 11872748.
    Citations: 232     Fields:    Translation:HumansCells
  167. Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002 Feb 21; 21(9):1346-58. PMID: 11857078.
    Citations: 35     Fields:    Translation:HumansCells
  168. Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002 Mar 08; 277(10):7875-81. PMID: 11751905.
    Citations: 39     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Chauhan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (575)
Explore
_
Co-Authors (65)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.